Search
South Carolina Paid Clinical Trials
A listing of 1222 clinical trials in South Carolina actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1213 - 1222 of 1222
South Carolina is currently home to 1222 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Charleston, Greenville, Spartanburg and Columbia. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Hyperacusis Activities Treatment-Online Study
Recruiting
Are you experiencing hyperacusis? If so, we are recruiting adults with hyperacusis to complete a clinical trial supported by the National Institutes of Health. The study involves participating in a remote counseling program and sound therapy trial for hyperacusis, Hyperacusis Activities Treatment-Online.
Conditions:
Hyperacusis
Tinnitus
Hearing Loss
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
Recruiting
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2022
Locations: Athersys Investigational Site 118, Columbia, South Carolina
Conditions: Ischemic Stroke
Safety and Durability of Sirolimus for Treatment of LAM
Recruiting
The MIDAS study aims to follow LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Lymphangioleiomyomatosis
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
Recruiting
The primary objective of the study is to characterize the concentrations of casirivimab+imdevimab in serum over time after a single subcutaneous (SC) administration
The secondary objectives of the study are:
To assess the safety and tolerability of SC or single administration of casirivimab+imdevimab
To assess the occurrence of grade ≥3 injection site reactions and grade ≥3 hypersensitivity reactions, in participants treated with SC doses of casirivimab+imdevimab
To assess the immunogenicity o... Read More
Gender:
All
Ages:
12 years and below
Trial Updated:
12/06/2021
Locations: Coastal Pediatric Research, Charleston, South Carolina
Conditions: COVID-19
CBT4CBT-Buprenorphine + Recovery Coach for Office-based Buprenorphine
Recruiting
To conduct an 8-week pilot, randomized trial evaluating the feasibility, acceptability, and efficacy of an integrated intervention involving CBT4CBT-Buprenorphine + Recovery Coach in a population of 60 individuals who meet current DSM criteria for opioid use disorder and are receiving buprenorphine treatment in primary care.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/30/2021
Locations: Internal Medicine Recovery Clinic, Greenville, South Carolina
Conditions: Opioid-use Disorder
Prospective US Radiofrequency SUI Trial
Recruiting
PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized, sham controlled, double blind study in premenopausal women with stress urinary incontinence. The study will be conducted in 390 subjects, randomized 2:1 with active or sham treatment. Study duration is 12 months post treatment. The primary objective is to evaluate the efficacy of the Viveve treatment, SUI protocol, in improving mild to moderate stress urinary incontinence (SUI), assessed using the 1-hour Pa... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
07/19/2021
Locations: Venus Gynecology, LLC, Myrtle Beach, South Carolina
Conditions: Urinary Incontinence, Stress
Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder
Recruiting
This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil locally to the vulvar-vaginal tissue.
Gender:
Female
Ages:
21 years and above
Trial Updated:
06/24/2021
Locations: Coastal Carolina Research Center, North Charleston, South Carolina
Conditions: Female Sexual Arousal Disorder
An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
Recruiting
The objectives of the trial are to evaluate the long-term efficacy and safety of HORIZANT (Gabapentin Enacarbil) 600 mg daily, for the treatment of RLS in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe primary RLS.
Gender:
All
Ages:
Between 13 years and 17 years
Trial Updated:
06/07/2021
Locations: SleepMed of South Carolina; SleepMed, Inc., Columbia, South Carolina
Conditions: RLS
An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
Recruiting
This is a multicenter, prospective, observational cohort registry in subjects receiving myelosuppressive chemotherapy for a non-myeloid malignancy who are considered to be at high risk for developing febrile neutropenia (FN).
Gender:
All
Ages:
18 years and above
Trial Updated:
12/21/2020
Locations: Coastal Cancer Center, Myrtle Beach, South Carolina
Conditions: Febrile Neutropenia, Non-myeloid Malignancy
Pulmonary Hypertension Association Registry
Recruiting
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S.
PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a... Read More
Gender:
All
Ages:
All
Trial Updated:
04/01/2020
Locations: AnMed Health, Anderson, South Carolina
Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
SOLEMN Study - Synergy Optical Coherence Tomography in Left Main PCI
Recruiting
BACKGROUD:
Percutaneous coronary intervention (PCI) is increasingly used to treat unprotected left main coronary artery stenosis. Protected LM PCI is considered standard of care in most centers.
OCT allows for precise determination of stent placement, stent expansion and apposition. The pattern of vessel healing can be very precisely studied if immediate post-stent implantation OCT/IVUS data is compared to the 6-month post-PCI interval.
While OCT cannot be optimally used for ostial lesion ima... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/14/2019
Locations: Ralph H. Johnson VA Medical Center, Charleston, South Carolina
Conditions: Percutaneous Coronary Intervention, Optical Coherence Tomography, In-stent Coronary Artery Restenosis